达格列净可改善英国二级保健糖尿病诊所患者的血糖控制和体重，随访 44 个月时观察到这一结果。
Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK.
机构信息
Department of Diabetes and Endocrinology, Morriston Hospital, Swansea Bay University Health Board, Swansea, SA6 8NL, UK.
Department of Diabetes and Endocrinology, Morriston Hospital, Swansea Bay University Health Board, Swansea, SA6 8NL, UK; Diabetes Research Group, Swansea University Medical School, Swansea University, Swansea, SA2 8PP, UK.
出版信息
Diabetes Metab Syndr. 2020 May-Jun;14(3):237-239. doi: 10.1016/j.dsx.2020.03.007. Epub 2020 Mar 26.
BACKGROUND AND AIMS
We examined HbA1c and cardiovascular risk factors with a median follow-up of 44 months therapy with dapagliflozin.
METHODS
We undertook a clinical practice evaluation of 101 patients attending our clinic.
RESULTS
Dapagliflozin resulted in a significant reduction in HbA1c 82.6 ± 15.7 v 68.7 ± 17.8 mmol/mol.
CONCLUSION
Dapagliflozin maintains glycaemic control along with sustained improvements in weight and no decline in renal function.
背景与目的
我们随访了 44 个月的达格列净治疗，分析糖化血红蛋白（HbA1c）与心血管风险因素。
方法
我们对 101 例在我院就诊的患者进行了临床实践评估。
结果
达格列净可使 HbA1c 显著降低，从 82.6±15.7mmol/mol 降至 68.7±17.8mmol/mol。
结论
达格列净在维持血糖控制的同时，持续改善体重，且肾功能无下降。
Zotero 插件